Atenolol 50mg Tablets

… (including sino-atrial block). - Untreated phaeochromocytoma. - Metabolic acidosis - Bradycardia (less than 45-50 beats per minute) - Hypotension - Severe peripheral circulatory disturbances - Concomitant intravenous use of verapamil or diltiazem - Severe asthma and severe chronic obstructive pulmonary disease such as airway obstructions.

… or to any of the excipients listed in section 6.1. - Second or third-degree heart block. - Cardiogenic shock. - Uncontrolled heart failure. - Sick sinus syndrome (including sino-atrial block). - Untreated phaeochromocytoma. - Metabolic acidosis - Bradycardia (less than 45-50 beats per minute) - Hypotension - Severe peripheral circulatory disturbances - Concomitant intravenous use of verapamil or diltiazem - Severe …

Atenolol, as with other beta blockers, should not be used in patients with any of the following: - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Second or third-degree heart block. - Cardiogenic shock. - Uncontrolled heart failure. - Sick sinus syndrome (including sino-atrial block). - Untreated phaeochromocytoma. - Metabolic acidosis - Bradycardia (less than 45-50 beats …

Atenolol, as with other beta blockers, should not be used in patients with any of the following: - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Second or third-degree heart block. - Cardiogenic shock. - Uncontrolled heart failure. - Sick sinus syndrome (including sino-atrial block). - Untreated phaeochromocytoma. - Metabolic acidosis …

… shock. - Uncontrolled heart failure. - Sick sinus syndrome (including sino-atrial block). - Untreated phaeochromocytoma. - Metabolic acidosis - Bradycardia (less than 45-50 beats per minute) - Hypotension - Severe peripheral circulatory disturbances - Concomitant intravenous use of verapamil or diltiazem - Severe asthma and severe chronic obstructive pulmonary disease such as airway obstructions.

… ed in section 6.1. - Second or third-degree heart block. - Cardiogenic shock. - Uncontrolled heart failure. - Sick sinus syndrome (including sino-atrial block). - Untreated phaeochromocytoma. - Metabolic acidosis - Bradycardia (less than 45-50 beats per minute) - Hypotension - Severe peripheral circulatory disturbances - Concomitant intravenous use of verapamil or diltiazem - Severe asthma and severe chr …

… ytoma. - Metabolic acidosis - Bradycardia (less than 45-50 beats per minute) - Hypotension - Severe peripheral circulatory disturbances - Concomitant intravenous use of verapamil or diltiazem - Severe asthma and severe chronic obstructive pulmonary disease such as airway obstructions.

… ytoma. - Metabolic acidosis - Bradycardia (less than 45-50 beats per minute) - Hypotension - Severe peripheral circulatory disturbances - Concomitant intravenous use of verapamil or diltiazem - Severe asthma and severe chronic obstructive pulmonary disease such as airway obstructions.

… ers, should not be used in patients with any of the following: - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Second or third-degree heart block. - Cardiogenic shock. - Uncontrolled heart failure. - Sick sinus syndrome (including sino-atrial block). - Untreated phaeochromocytoma. - Metabolic acidosis - Bradycardia (less than 45-50 beats per minute) - Hypoten …

Atenolol, as with other beta blockers, should not be used in patients with any of the following: - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Second or third-degree heart block. - Cardiogenic shock. - Uncontrolled heart failure. - Sick sinu …

… th the sensitivity towards allergens and the seriousness of anaphylactic reactions. Atenolol may reduce the efficacy of the usual dose of adrenaline (epinephrine) used to treat allergic reactions. Hypersensitivity: atenolol may cause a hypersensitivity reaction including angio-oedema and urticaria. (see section 4.8) Psoriasis: patients with anamnestically known psoriasis should take beta-blockers only after careful consideration. Elderly: these patients should be treated with caution, starting with a lower d …

… persensitivity reaction including angio-oedema and urticaria. (see section 4.8) Psoriasis: patients with anamnestically known psoriasis should take beta-blockers only after careful consideration. Elderly: these patients should be treated with caution, starting with a lower dosage Surgery: When a patient has been scheduled for surgery, and it has been decided to interupt beta-blockade, therapy should be discontinued for at least 24 hours. Continuation of beta-blockade reduce …

… ionally, some increase in airways resistance may occur in asthmatic patients however, and this may usually be reversed by commonly used dosage of bronchodilators such as salbutamol or isoprenaline. This medicine contains less than 1 mmol sodium (23mg) per tablet, that is to say essentially 'sodium free'.

… ed in uncontrolled heart failure (see section 4.3), may be used in patients whose signs of heart failure have been controlled. Similarly, care must be taken with patients with poor cardiac reserve. Ischaemic Heart disease: especially in patients with ischaemic heart disease, treatment should not be discontinued suddenly. The dosage should be gradually reduced, i.e. over 1-2 weeks, if necessary at the same time initiating replacement therapy, to prevent exacerbation of angina pectoris. In addition, hypertension and arrhythmias may develop. Furthermore, there is a risk of myocardial infarction and sudden death. Patients should be followed during withdrawal, especially those with ischaemic heart disease. Untreated Congestive Heart disease: beta-blockers should not be used in such patients. The condition should be stabilised first. First Degree Heart Block: due to its negative effect on conduction …

… flet: Do not take this medicine if you have a history of wheezing or asthma. Consult your doctor or pharmacist first. Labels: Do not take this medicine if you have a history of wheezing or asthma. Renal impairment: In patients with impaired renal function, the dose should be adjusted to reduce glomerular filtration rate (see section 4.2). Since atenolol is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearance of below 35 ml/min/1.73 m2. Treated phaeochromocytoma: atenolol should be used with blood pressure monitoring in patients with treated phaeochromocytoma. Hypoglycaemia: the symptoms of hypoglycaemia may be masked by atenolo …

… s could further increase the risk of severe hypoglycaemia when used concurrently with sulfonylureas. Diabetic patients should be advised to carefully monitor blood glucose levels. (see Section 4.5) Thyrotoxicosis: Beta-blockade may mask cardiovascular signs of thyrotoxicosis. Allergies: Atenolol may increase both the sensitivity towards allergens and the seriousness of anaphylactic reactions. Atenolol may reduce the efficacy of the usual dose of adrenaline (epinephrine) …

… ed in uncontrolled heart failure (see section 4.3), may be used in patients whose signs of heart failure have been controlled. Similarly, care must be taken with patients with poor cardiac reserve. Ischaemic Heart disease: especially in patients with ischaemic heart disease, treatment should not be discontinued suddenly. The dosage should be gradually reduced, i.e. over 1-2 weeks, if necessary at the same time initiating replacement therapy, to prevent exacerbation of angina pectoris. In addition, hypertension and arrhythmias may develop. Furthermore, there is a risk of myocardial infarction and sudden death. Patients should be followed during withdrawal, especially those with ischaemic heart disease. Untreated Congestive Heart disease: beta-blockers should not be used in such patients. The condition should be stabilised first. First Degree Heart Block: due to its negative effect on conduction …

• Alcohol: concomitant use with alcohol may lead to an enhanced hypotensive effect. • Alpha blockers – some patients experience acute postural hypotension, tachycardia and palpitations when they start to take certain alpha blockers (e.g. prazosin, alfuzosin, and terazosin), this c …

… ncrease the risk of severe hypoglycaemia. Beta-adrenergic blockade may prevent the appearance of signs of hypoglycaemia (tachycardia). • Baclofen: Causes an increased antihypertensive activity. • Contrast media, iodinated: Atenolol may impede the compensatory cardiovascular reactions associated with hypotension or shock induced by iodinated contrast products. • Calcium channel blockers: concomitant administration of dihydropyridine derivatives (e.g. nifedipine), may increase the risk of hypotension, and in patients with latent cardiac insufficiency, tre …

… nd second trimesters (especially hypoglycaemia, hypotension and bradycardia). Beta-blockers reduce placental perfusion which may result in intra-uterine deaths, immature and premature deliveries. Breast-feeding Atenolol is excreted into breast milk reaching higher concentration than in plasma. A risk in the breastfed child cannot be excluded (beta-blockade). Neonates born to mothers who are receiving ate …

… uded Administration of atenolol in pregnancy has been associated with reduced foetal growth. Atenolol has been used under close supervision for the treatment of hypertension in the third trimester. On the basis of its pharmacological properties, adverse effects may occur in the foetus and newborn infant, if used in the first and second trimesters (especially hypoglycaemia, hypotension and bradycardia). Beta-blockers reduce placental perfusion which may result in intra-uterine deaths, immature and premature deliveries. Breast-feeding Atenolol is excreted into breast milk reaching higher concentration than in plasma. A risk in the breastfed child cannot be excluded (beta-blockade). Neonates born to mothers wh …

… uded Administration of atenolol in pregnancy has been associated with reduced foetal growth. Atenolol has been used under close supervision for the treatment of hypertension in the third trimester. On the basis of its pharmacological properties, adverse effects may occur in the foetus and newborn infant, if used in the first and second trimesters (especially hypoglycaemia, hypotension and bradycardia). Beta-blockers reduce placental perfusion which may result in intra-uterine deaths, immature and premature deliveries. Breast-feeding Atenolol is excreted into breast milk reaching higher concentration than in plasma. A risk in the breastfed child cannot be excluded (beta-blockade). Neonates born to mothers wh …

Pregnancy There are no adequate data from the use of atenolol in pregnant women to determine its potential harmfulness. Atenolol crosses the placental barrier and appears in the cord blood. No studies have …

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.

Not found in the sections read for this label. Not the same as the label being silent.